Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Working Capital Changes: 2021-2024

Historic Other Working Capital Changes for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to -$5.0 million.

  • Amylyx Pharmaceuticals' Other Working Capital Changes rose 183.90% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.8 million, marking a year-over-year increase of 71.68%. This contributed to the annual value of -$5.0 million for FY2024, which is 254.62% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Other Working Capital Changes of -$5.0 million as of FY2024, which was down 254.62% from $3.2 million recorded in FY2023.
  • Over the past 5 years, Amylyx Pharmaceuticals' Other Working Capital Changes peaked at $5.2 million during FY2022, and registered a low of -$5.0 million during FY2024.
  • For the 3-year period, Amylyx Pharmaceuticals' Other Working Capital Changes averaged around $1.2 million, with its median value being $3.2 million (2023).
  • In the last 5 years, Amylyx Pharmaceuticals' Other Working Capital Changes climbed by 16.38% in 2022 and then crashed by 254.62% in 2024.
  • Yearly analysis of 4 years shows Amylyx Pharmaceuticals' Other Working Capital Changes stood at $4.5 million in 2021, then climbed by 16.38% to $5.2 million in 2022, then slumped by 38.21% to $3.2 million in 2023, then tumbled by 254.62% to -$5.0 million in 2024.